BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 15, 2026
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

USGI gears up for pivotal trial; gains traction from Europe studies

Oct. 14, 2013
By Omar Ford

First patient receives treatmentin Boston Sci's MAJESTIC trial

Oct. 11, 2013
By Omar Ford

Endotronix develops implantablesensor for chronic HF patients

Oct. 10, 2013
By Omar Ford

Not just business as usual for med-tech

Oct. 9, 2013
By Omar Ford
Medical companies that are still entertaining the notion that business can continue as usual – that somehow the model of collaboration between firms and physicians is enough to foster innovation – are in for a rude awakening. We live in the “mobile information age,” where customers patients aren’t tethered to bulky computers or laptops to do the necessary research on a treatment method that might be suitable for them. All they need to do is need pull out their smart phone or tablet and at the touch of an ap, they have about 75% of the information they have...
Read More

Aptus eyes favorable results from ANCHOR post-market study

Oct. 9, 2013
By Omar Ford
Aptus Endosystems (Sunnyvale, California), a company pioneering solutions to enhance aneurysm repair, reported positive initial results from its ANCHOR post-market registry evaluating the use of the Heli-FX EndoAnchor System in endovascular aneurysm repair (EVAR).
Read More

MDD's 3Q13 Report: Med-tech investments dip ever-so slightly in 3Q13

Oct. 8, 2013
By Omar Ford

PwC report urges med-tech to think outside of the box

Oct. 8, 2013
By Omar Ford

Invuity lights the way for minimal access surgery

Oct. 8, 2013
By Omar Ford

OrthoSensor in plan to market Verasense OUS

Oct. 7, 2013
By Omar Ford
Coming off a successful approval from the FDA, OrthoSensor (Dania Beach, Florida) reported that it has received CE mark approval for its Verasense Knee System, and plans to launch the device in the European markets.
Read More

Newco on the Go: Vital Connect's HealthPatch next step in wearable biosensor tech

Oct. 4, 2013
By Omar Ford
Unsustainable trends including aging demographics, chronic disease, cost of care, and caregiver shortage are driving a global healthcare crisis and even threatening the global economy. Wearable biosensor technology that remotely connects patients and caregivers is the force-multiplier to address these global challenges. The global market for biosensors to monitor health for aging, clinical, and consumer health will exceed $100 billion annually by 2015.
Read More
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 14, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Lung cancer illustration

    LINC01116 has prognostic value in lung cancer, study shows

    BioWorld MedTech
    Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing